The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males.
BACKGROUND
Alterations of sperm number and motility are found in hyperprolactinaemic men. Cabergoline treatment reverses alterations in semen. No information is currently available on the quality of seminal tests in hyperprolactinemia in response to cabergoline treatment.


OBJECTIVE
To further investigate the effect of hyperprolactinaemia and its treatment with cabergoline on semen quality.


METHODS
Forty-three men with hyperprolactinaemia (32 macro- and 11 micro-prolactinomas); 60 healthy men served as control.


METHODS
Live spermatozoa count, sperm membrane function, kinetic index, nuclear DNA integrity, sperm curvilinear and linear velocity and amplitude of lateral movement of the sperm head were investigated before and after 6 and 24 months of treatment with cabergoline.


METHODS
Open prospective.


RESULTS
At study entry, semen functional tests were severely and similarly impaired both in patients with macro- and micro-prolactinomas compared to controls. After 6 and 12 months of treatment there was a significant improvement of semen quality in patients achieving normalization of prolactin levels, although most of the parameters remained lower than in controls. After 24 months of treatment, seminal fluid characteristics were similar to the controls except for live spermatozoa count, sperm membrane function, sperm kinetic index and sperm nuclear DNA integrity, which remained abnormal in 9.3-53% of the patients.


CONCLUSIONS
Twenty-four months of cabergoline treatment restored gonadal function in 66.7% of men with hyperprolactinaemia.
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy.
Michele
M
De Rosa
Antonio
A
Ciccarelli
Stefano
S
Zarrilli
Ermelinda
E
Guerra
Maria
M
Gaccione
Antonella
A
Di Sarno
Gaetano
G
Lombardi
Annamaria
A
Colao
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000077465:Cabergoline; D016022:Case-Control Studies; D004334:Drug Administration Schedule; D004873:Ergolines / Q000008:administration & dosage*; D006062:Gonadotropins / Q000097:blood; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D011388:Prolactin / Q000037:antagonists & inhibitors / Q000097:blood; D015175:Prolactinoma / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D012661:Semen / Q000187:drug effects* / Q000502:physiology; D013076:Sperm Count / Q000379:methods; D013094:Spermatozoa / Q000502:physiology; D013739:Testosterone / Q000097:blood; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D004873:Ergolines; D006062:Gonadotropins; D013739:Testosterone; D011388:Prolactin; D000077465:Cabergoline